clinvestКачественная клиническая практикаKachestvennaya Klinicheskaya Praktika = Good Clinical Practice2588-05192618-8473ООО «Издательство ОКИ10.37489/2588-0519-2020-S4-60-63clinvest-528Research ArticleАКТУАЛЬНЫЕ ОБЗОРЫACTUAL REVIEWВозможность применения анакинры при COVID-19Possibilities for the use of anakinra in COVID-19https://orcid.org/0000-0003-0623-7263ОтделеновВ. А.OtdelenovV. A.

Отделенов Виталий Александрович – доцент кафедры клинической фармакологии и терапии. SPIN-код: 8357-5770

Москва

Otdelenov Vitaly A. – Associate Professor of the Department of Clinical Pharmacology and Therapy. SPIN code: 8357-5770

Moscow

https://orcid.org/0000-0002-6636-3950МатвеевА. В.MatveevA. V.

Матвеев Александр Витальевич – к. м. н., доцент кафедры клинической фармакологии и терапии. SPIN-код: 8518-1320

Москва

Matveev Alexander V. – Candidate of Medical Sciences, Associate Professor of the Department of Clinical Pharmacology and Therapy. SPIN code: 8518-1320

Moscow

https://orcid.org/0000-0002-4496-3680СычёвД. А.SychevD. A.

Сычёв Дмитрий Алексеевич – д. м. н., профессор, член-корр. РАН, ректор, зав. кафедрой клинической фармакологии и терапии. SPIN-код: 4525-7556

Москва

Sychev Dmitry A. – Doctor of Medical Sciences, Professor, Corresponding Member RAS, Rector, Head. Department of Clinical Pharmacology and Therapy. SPIN code: 4525-7556

Moscow

dmitriy.alex.sychev@gmail.comФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииРоссияRussian Medical Academy of Continuing Professional Education of the Ministry of Health of RussiaRussian Federation20202810202004SФармаCOVID6063Copyright © Отделенов В.А., Матвеев А.В., Сычёв Д.А., 20202020Отделенов В.А., Матвеев А.В., Сычёв Д.А.Otdelenov V.A., Matveev A.V., Sychev D.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.clinvest.ru/jour/article/view/528

В настоящее время применение анакинры в качестве патогенетической терапии «цитокинового шторма», наблюдающегося при тяжёлом течении COVID-19, не может быть рекомендовано для рутинного применения вне клинического исследования.

The use of anakinra cannot be currently recommended outside of clinical trials as pathogenetic treatment of “cytokine storm” in severe COVID-19.

коронавирусанакинраCOVID-19coronavirusanakinraCOVID-19ReferencesKINERET ® (anakinra) injection, for subcutaneous use. FULL PRESCRIBING INFORMATION [Internet]. [cited 2020 May 25]; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103950s5182lbl.pdfKINERET ® (anakinra) injection, for subcutaneous use. FULL PRESCRIBING INFORMATION [Internet]. [cited 2020 May 25]; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103950s5182lbl.pdfChannappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017 Jul;39(5):529-539. DOI: 10.1007/s00281-017-0629-xChannappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017 Jul;39(5):529-539. DOI: 10.1007/s00281-017-0629-xWong CK et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol. 2004 Apr;136(1):95-103. DOI: 10.1111/j.1365-2249.2004.02415.xWong CK et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol. 2004 Apr;136(1):95-103. DOI: 10.1111/j.1365-2249.2004.02415.xGong J et al. Correlation Analysis Between Disease Severity and Inflammation-related Parameters in Patients with COVID-19 Pneumonia. MedRxiv. 2020 February 27. DOI: 10.1101/2020.02.25.20025643.Gong J et al. Correlation Analysis Between Disease Severity and Inflammation-related Parameters in Patients with COVID-19 Pneumonia. MedRxiv. 2020 February 27. DOI: 10.1101/2020.02.25.20025643.Временные методические рекомендации Министерства здравоохранения РФ по профилактике, диагностике и лечению новой коронавирусной инфекции (COVID-19). Версия 6 (28.04.2020) [Электронный ресурс]. 2020. Доступно по: https://clck.ru/NCM6x Ссылка активна на 25.05.2020Temporary guidelines of the Ministry of health of the Russian Federation for the prevention, diagnosis and treatment of new coronavirus infection (COVID-19). Version 6 (28.04.2020). (In Russ). Доступно по: https://clck.ru/NCM6x Ссылка активна на 25.05.2020UW Medicine COVID-19 Resource Site [Internet]. University of Washington. 2020. [cited 2020 May 25]; Available from: https://covid-19.uwmedicine.org/Pages/default.aspxUW Medicine COVID-19 Resource Site [Internet]. University of Washington. 2020. [cited 2020 May 25]; Available from: https://covid-19.uwmedicine.org/Pages/default.aspxColleges C.A.M. and N. National COVID-19 Clinical Evidence Taskforce [Internet]. 2020. P. Guidelines. [cited 2020 May 25]; Available from: https://covid19evidence.net.au/Colleges C.A.M. and N. National COVID-19 Clinical Evidence Taskforce [Internet]. 2020. P. Guidelines. [cited 2020 May 25]; Available from: https://covid19evidence.net.au/Coronavirus Disease 2019 (COVID-19) Treatment Guidelines [Internet]. [cited 2020 May 25]; Available from: https://www.covid19treatmentguidelines.nih.gov/Coronavirus Disease 2019 (COVID-19) Treatment Guidelines [Internet]. [cited 2020 May 25]; Available from: https://www.covid19treatmentguidelines.nih.gov/Brigham and Women’s Hospital COVID-19 Clinical Guidelines Therapeutics — Anti-IL-1 Agents (Anakinra, Canakinumab, Rilonacept) [Internet]. [cited 2020 May 22]; Available from: https://covidprotocols.org/protocols/therapeutics/#anti-il-1-agents-anakinra-canakinumab-rilonaceptBrigham and Women’s Hospital COVID-19 Clinical Guidelines Therapeutics — Anti-IL-1 Agents (Anakinra, Canakinumab, Rilonacept) [Internet]. [cited 2020 May 22]; Available from: https://covidprotocols.org/protocols/therapeutics/#anti-il-1-agents-anakinra-canakinumab-rilonaceptFilocamo G et al. Use of anakinra in severe COVID-19: a case report. Int J Infect Dis. 2020 Jul;96:607-609. DOI: 10.1016/j.ijid.2020.05.026Filocamo G et al. Use of anakinra in severe COVID-19: a case report. Int J Infect Dis. 2020 Jul;96:607-609. DOI: 10.1016/j.ijid.2020.05.026Franzetti M et al. Interleukin-1 receptor antagonist anakinra in association with remdesivir in severe Coronavirus disease 2019: A case report. Int J Infect Dis. 2020 Aug;97:215-218. DOI: 10.1016/j.ijid.2020.05.050Franzetti M et al. Interleukin-1 receptor antagonist anakinra in association with remdesivir in severe Coronavirus disease 2019: A case report. Int J Infect Dis. 2020 Aug;97:215-218. DOI: 10.1016/j.ijid.2020.05.050Lopalco G et al. Safety profile of anakinra in the management of rheumatologic, metabolic and autoinflammatory disorders. Clin Exp Rheumatol. Italy, 2016. Vol. 34, No 3. P. 531- 538.Lopalco G et al. Safety profile of anakinra in the management of rheumatologic, metabolic and autoinflammatory disorders. Clin Exp Rheumatol. Italy, 2016. Vol. 34, No 3. P. 531- 538.Разъяснения Министерства здравоохранения РФ от 30 октября 2018 г. О ввозе в РФ конкретной партии незарегистрированных лекарственных средств, предназначенных для оказания медицинской помощи по жизненным показаниям конкретного пациента. Доступно по: https://www.garant.ru/products/ipo/prime/doc/71995356/ Ссылка активна на 27.05.2020Explanations of the Ministry of health of the Russian Federation dated October 30, 2018 About importation to the Russian Federation of the specific party of the unregistered medicines intended for rendering medical care on vital indications of the specific patient. (In Russ). Доступно по: https://www.garant.ru/products/ipo/prime/doc/71995356/ Ссылка активна на 27.05.2020

The authors declare that there are no conflicts of interest present.